Cargando…
History of Extensive Disease Small Cell Lung Cancer Treatment: Time to Raise the Bar? A Review of the Literature
SIMPLE SUMMARY: Small cell lung cancer (SCLC) remains the most aggressive form of neuroendocrine tumor of the lung, for which treatment options remain limited. The introduction of immune checkpoint inhibitors has modified for the first time the therapeutic strategies in patients with extensive disea...
Autores principales: | Lazzari, Chiara, Mirabile, Aurora, Bulotta, Alessandra, Viganó, Maria Grazia, Ogliari, Francesca Rita, Ippati, Stefania, Dell’Oca, Italo, Santarpia, Mariacarmela, Lorusso, Vincenza, Reck, Martin, Gregorc, Vanesa |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7957518/ https://www.ncbi.nlm.nih.gov/pubmed/33673630 http://dx.doi.org/10.3390/cancers13050998 |
Ejemplares similares
-
Combination of immunotherapy with chemotherapy and radiotherapy in lung cancer: is this the beginning of the end for cancer?
por: Lazzari, Chiara, et al.
Publicado: (2018) -
Intratumoral Cellular Heterogeneity: Implications for Drug Resistance in Patients with Non-Small Cell Lung Cancer
por: Gregorc, Vanesa, et al.
Publicado: (2021) -
PD-1 Inhibitors-Related Neurological Toxicities in Patients with Non-Small-Cell Lung Cancer: A Literature Review
por: Mirabile, Aurora, et al.
Publicado: (2019) -
Metabolism and Immune Modulation in Patients with Solid Tumors: Systematic Review of Preclinical and Clinical Evidence
por: Mirabile, Aurora, et al.
Publicado: (2020) -
Mechanisms of resistance to osimertinib
por: Lazzari, Chiara, et al.
Publicado: (2020)